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1. INTRODUCTION {#ajmgb32695-sec-0001}
===============

Attention‐deficit/hyperactivity disorder (ADHD), a neurodevelopmental disorder, is one of the most common psychiatric and behavioral disorders in children and adolescents, with more than 5% of the pediatric population affected worldwide, often persisting into adulthood (Polanczyk, Willcutt, Salum, Kieling, & Rohde, [2014](#ajmgb32695-bib-0053){ref-type="ref"}; Thomas, Sanders, Doust, Beller, & Glasziou, [2015](#ajmgb32695-bib-0065){ref-type="ref"}). Although both the cause and pathophysiology of ADHD are largely unknown, there is a growing body of evidence supporting interactions of multiple genetic and environmental factors during early development thus providing a neurobiological susceptibility to the disorder (Curatolo, D\'Agati, & Moavero, [2010](#ajmgb32695-bib-0014){ref-type="ref"}).

ADHD diagnosis in children and adolescents is more frequent in boys than girls, with males being 2--4 times more likely to meet diagnostic criteria than females (Davies, [2014](#ajmgb32695-bib-0015){ref-type="ref"}). Moreover, age‐at‐onset, severity, and comorbidities were found to be sex‐dependent (Davies, [2014](#ajmgb32695-bib-0015){ref-type="ref"}). Just recently, a fMRI study reported significant volume reduction in putamen and thalamus of girls with ADHD, whereas a significant subcortical volume reduction was observed in ADHD patients independent of sex (Rosch et al., [2018](#ajmgb32695-bib-0057){ref-type="ref"}). Subsequently, the authors discuss the importance to study the trajectories of such neurodevelopmental disorders together with the sex‐dimorphic neuroanatomical development, as maturation timelines between boys and girls are substantially different (Rosch et al., [2018](#ajmgb32695-bib-0057){ref-type="ref"}). Differential susceptibility to pre‐ and postnatal stress has been discussed to affect brain development and maturation in a sex‐dimorphic manner, which was hypothesized to add to the genetic load that already leads to the different ADHD frequencies between genders (Van den Bergh et al., [2017](#ajmgb32695-bib-0068){ref-type="ref"}). The aforementioned recent findings as examples, point to the importance of studying genetic susceptibility for ADHD not only at the diagnostic level, but also at age‐at‐onset and sex differences.

Wnt‐signaling pathways orchestrate cellular proliferation, polarity and differentiation; processes that are crucial for healthy tissue morphogenesis, especially in the embryonic stage (MacDonald, Tamai, & He, [2009](#ajmgb32695-bib-0041){ref-type="ref"}). Two most known Wnt‐pathways exist: a canonical pathway and a noncanonical pathway. In the canonical pathway, the secreted Wnt glycoproteins bind to Frizzled receptors, as well as to either lipoprotein receptor‐related protein 5 (LRP5) or LRP6 coreceptors, to initiate a signaling cascade, in which downstream β‐catenin is harnessed as a cotranscription factor in the nucleus (Tamai et al., [2000](#ajmgb32695-bib-0061){ref-type="ref"}; Wehrli et al., [2000](#ajmgb32695-bib-0074){ref-type="ref"}). Canonical Wnt‐signaling has a pivotal role both in the developing and mature brain. During development the Wnt pathway regulates the balance between proliferation and differentiation of neuronal progenitor and precursor cells (Noelanders & Vleminckx, [2016](#ajmgb32695-bib-0049){ref-type="ref"}). Furthermore, Wnt‐signaling also affects neuronal stem cell proliferation and differentiation in the mature brain (Bengoa‐Vergniory & Kypta, [2015](#ajmgb32695-bib-0007){ref-type="ref"}), and it has a supportive role in the maturation of dendrites and spines (Hussaini et al., [2014](#ajmgb32695-bib-0029){ref-type="ref"}).

Several neurodevelopmental psychiatric disorders have been shown to overlap not only at the behavioral levels, but also at the genetic levels, as it has been repeatedly shown among ADHD, autism spectrum disorder (ASD), intellectual disability (ID), bipolar disorder, and psychosis (Brainstorm Consortium et al., [2018](#ajmgb32695-bib-0004){ref-type="ref"}; Bulik‐Sullivan et al., [2015](#ajmgb32695-bib-0008){ref-type="ref"}; Khanzada, Butler, & Manzardo, [2017](#ajmgb32695-bib-0032){ref-type="ref"}; Polimanti & Gelernter, [2017](#ajmgb32695-bib-0054){ref-type="ref"}; Taurines et al., [2012](#ajmgb32695-bib-0062){ref-type="ref"}; van Hulzen et al., [2017](#ajmgb32695-bib-0069){ref-type="ref"}; Zhao & Nyholt, [2017](#ajmgb32695-bib-0082){ref-type="ref"}). Interestingly, the Wnt‐signaling pathway seems to be one of the overlapping pathways, showing pathological alterations in the above disorders (Kwan, Unda, & Singh, [2016](#ajmgb32695-bib-0034){ref-type="ref"}; Mulligan & Cheyette, [2017](#ajmgb32695-bib-0047){ref-type="ref"}; Oron & Elliott, [2017](#ajmgb32695-bib-0050){ref-type="ref"}; Zhao & Nyholt, [2017](#ajmgb32695-bib-0082){ref-type="ref"}). For example, genome‐wide association studies (GWAS) reported the 4p15.31 region to be nominally associated with ADHD (not reaching genome‐wide *p*‐value \< 5 × 10^−8^), where the *KCNIP4* (potassium voltage‐gated channel interacting protein 4) gene is located (Lasky‐Su et al., [2008](#ajmgb32695-bib-0035){ref-type="ref"}; Lesch et al., [2008](#ajmgb32695-bib-0037){ref-type="ref"}; Neale et al., [2008](#ajmgb32695-bib-0048){ref-type="ref"}). KCINP4 is known to play a role in the negative feedback loop of the Wnt/β‐catenin pathway. In a later candidate gene study, six *KCNIP4* single markers and one haplotype block were found to associate with adult ADHD (aADHD; Weissflog et al., [2013](#ajmgb32695-bib-0076){ref-type="ref"}). Another GWAS analyzed a subpopulation of ADHD cases, which had concomitant oppositional defiant disorder, and found the β‐catenin‐pathway to be highlighted in the enrichment analysis (Aebi et al., [2015](#ajmgb32695-bib-0001){ref-type="ref"}). Moreover, Wnt‐signaling has been also associated with learning and memory, especially with deficits in working and spatial memory (Fortress, Schram, Tuscher, & Frick, [2013](#ajmgb32695-bib-0023){ref-type="ref"}; Maguschak & Ressler, [2011](#ajmgb32695-bib-0042){ref-type="ref"}; Maguschak & Ressler, [2012](#ajmgb32695-bib-0043){ref-type="ref"}). Epidemiological studies pointed to Wnt‐involvement in behavioral problems including hyperactivity (Hussaini et al., [2014](#ajmgb32695-bib-0029){ref-type="ref"}; Maguschak & Ressler, [2012](#ajmgb32695-bib-0043){ref-type="ref"}). In ASD, highly comorbid disorder in ADHD, a wide range of evidence points to the involvement of the Wnt‐pathway (Belinson et al., [2016](#ajmgb32695-bib-0006){ref-type="ref"}; Caracci, Avila, & De Ferrari, [2016](#ajmgb32695-bib-0009){ref-type="ref"}; Packer, [2016](#ajmgb32695-bib-0051){ref-type="ref"}; Zhang, Yuan, Wang, & Li, [2014](#ajmgb32695-bib-0081){ref-type="ref"}). Lastly, an indirect evidence of the Wnt‐signaling involvement in ADHD could be demonstrated by our research group, showing that methylphenidate (a psychostimulant and one of the first line treatment in ADHD therapy) influences cell proliferation and differentiation supporting neuronal maturation (Grünblatt, Bartl, & Walitza, [2018](#ajmgb32695-bib-0025){ref-type="ref"}). More specifically, we could demonstrate that methylphenidate activates Wnt‐signaling, which was not due to the dopamine transporter inhibition---the main know therapeutic mechanism of this drug---as selective dopamine transporter inhibitor GBR‐12909 treatment demonstrated the opposite effects (Grünblatt et al., [2018](#ajmgb32695-bib-0025){ref-type="ref"}).

As the two possible coreceptors LRP5 and LRP6 play major role in Wnt‐pathway activation, we conducted literature search selecting functional gene variants affecting either receptor function, gene expression or epigenetic modulations, such as histone modifications or DNA methylation levels (see Table [1](#ajmgb32695-tbl-0001){ref-type="table"} and Supporting Information Table S1). Published genetic associations with psychiatric, neurological, or metabolic diseases are also listed in Table [1](#ajmgb32695-tbl-0001){ref-type="table"}. Based on the hypothesis of the involvement of Wnt‐signaling in ADHD, we carried out genetic association analyses of the selected four *LRP5* and *LRP6* gene variants with ADHD in three independent European samples (total 2,917 participants), and a meta‐analysis with previously published data. Furthermore, due to sex‐discrepancy in ADHD frequency, we stratified the analysis according to sex and compared our results to the recent Psychiatric Genomic Consortium (PGC) ADHD GWAS results (Demontis et al., [2017](#ajmgb32695-bib-0019){ref-type="ref"}; Martin et al., [2018](#ajmgb32695-bib-0045){ref-type="ref"}).

###### 

Literature summary linking LRP5 and LRP6 gene variants with ADHD and other disorders

  Gene   SNP[a](#ajmgb32695-note-0002){ref-type="fn"}   Functional effects in HEK293T cells                                                                                                                                                                Functional effects in neuronal cells or animal models                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Association studies
  ------ ---------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  LRP5   Loci/gene                                      NA                                                                                                                                                                                                 Overexpression of *LRP5* & *LRP6* in SH‐SY5Y cells protected against oxidative stress and reduced tau phosphorylation (Zhang, Bahety, & Ee, [2015](#ajmgb32695-bib-0080){ref-type="ref"}).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  BMD (Estrada et al., [2012](#ajmgb32695-bib-0022){ref-type="ref"}); schizophrenia and major depressive disorder (Zhao & Nyholt, [2017](#ajmgb32695-bib-0082){ref-type="ref"})
  LRP5   rs4988319                                      NA                                                                                                                                                                                                 NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          BMD (Tran, Nguyen, Eisman, & Nguyen, [2008](#ajmgb32695-bib-0066){ref-type="ref"}); Wagner syndrome (Rothschild et al., [2013](#ajmgb32695-bib-0058){ref-type="ref"})
  LRP5   rs3736228                                      LRP5‐V1330 demonstrated reduced Wnt3a signaling compared to wild‐type (Urano et al., [2009](#ajmgb32695-bib-0067){ref-type="ref"})                                                                 NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Males low diastolic blood pressure (Suwazono et al., [2006](#ajmgb32695-bib-0060){ref-type="ref"}); obesity and BMI (Guo et al., [2006](#ajmgb32695-bib-0026){ref-type="ref"}); male bone fractures (van Meurs et al., [2006](#ajmgb32695-bib-0070){ref-type="ref"}); BMD (Estrada et al., [2012](#ajmgb32695-bib-0022){ref-type="ref"}; Tran et al., [2008](#ajmgb32695-bib-0066){ref-type="ref"}); risk of having metabolic syndrome (Yang et al., [2013](#ajmgb32695-bib-0079){ref-type="ref"})
  LRP6   Loci/gene                                      NA                                                                                                                                                                                                 Neural tube defects in humans as well as in mice (Allache et al., [2014](#ajmgb32695-bib-0003){ref-type="ref"}; Carter et al., [2005](#ajmgb32695-bib-0010){ref-type="ref"}; Kokubu et al., [2004](#ajmgb32695-bib-0033){ref-type="ref"}; Lei et al., [2015](#ajmgb32695-bib-0036){ref-type="ref"}; Pinson, Brennan, Monkley, Avery, & Skarnes, [2000](#ajmgb32695-bib-0052){ref-type="ref"}); *Lrp6* mutant mice (insertion mutation) demonstrate suboptimal development of brain regions (e.g., forebrain, midbrain, and hindbrain), and defected neurogenesis of dopaminergic neurons (Castelo‐Branco et al., [2010](#ajmgb32695-bib-0011){ref-type="ref"}; Pinson et al., [2000](#ajmgb32695-bib-0052){ref-type="ref"}; Zhou, Zhao, & Pleasure, [2004](#ajmgb32695-bib-0083){ref-type="ref"}), as well as age‐dependent synaptic loss and memory impairments in these mice (Liu et al., [2014](#ajmgb32695-bib-0039){ref-type="ref"})   AD, diabetes mellitus type 2, osteoporosis (Wang, Luo, Xu, Zhou, & Zhang, [2017](#ajmgb32695-bib-0072){ref-type="ref"})
  LRP6   rs1012672                                      LRP6‐variant demonstrated reduced Wnt signaling compared to wild‐type (Xu et al., [2014](#ajmgb32695-bib-0078){ref-type="ref"})                                                                    NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          AD (miR‐141 miR‐23a miR‐23b; Mallick & Ghosh, [2011](#ajmgb32695-bib-0044){ref-type="ref"}); AD (Alarcon et al., [2013](#ajmgb32695-bib-0002){ref-type="ref"}; De Ferrari et al., [2007](#ajmgb32695-bib-0018){ref-type="ref"})
  LRP6   rs2302685                                      LRP6‐variant demonstrated reduced Wnt signaling compared to wild‐type (De Ferrari et al., [2007](#ajmgb32695-bib-0018){ref-type="ref"}; Xu et al., [2014](#ajmgb32695-bib-0078){ref-type="ref"})   NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Risk of ischemic stroke (Harriott et al., [2015](#ajmgb32695-bib-0027){ref-type="ref"}); AD (Alarcon et al., [2013](#ajmgb32695-bib-0002){ref-type="ref"}; De Ferrari et al., [2007](#ajmgb32695-bib-0018){ref-type="ref"}); male bone fractures (van Meurs et al., [2006](#ajmgb32695-bib-0070){ref-type="ref"})

Abbreviations: AD = Alzheimer\'s disease; BMD = bone mineral density; BMI = body mass index; NA = not available.

Details on annotation, GTEx and epigenetic findings are presented in the Supporting Information Table S1.

2. METHODS {#ajmgb32695-sec-0002}
==========

2.1. Study samples {#ajmgb32695-sec-0003}
------------------

### 2.1.1. Zurich child and adolescent ADHD (cADHD) patients and parents including unrelated control‐sample {#ajmgb32695-sec-0004}

One hundred and ninety six Caucasian nuclear families (146 families with both parents and 50 families with one parent) were recruited and the index patients (aged 6--21 years) were phenotypically characterized in the outpatient units of the Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich. Families were included if at least the index patient fulfilled the diagnostic criteria for ADHD (F90.0 or F90.1) according to ICD‐10 (Dilling, Freyberger, & Stieglitz, [1996](#ajmgb32695-bib-0020){ref-type="ref"}; World Health Organization, [2016](#ajmgb32695-bib-0077){ref-type="ref"}). Accordingly, this resulted in 727 individuals (258 probands with ADHD (males = 179, females = 79) and 469 controls (males = 203, females = 266); total of 382 male and 345 female participants). The ADHD diagnoses of the parents and siblings were reported by the parents. The psychiatric diagnostics of the index patient was assessed by a child and adolescent psychiatrist or psychologist under supervision of a senior psychiatrist in the clinic. The index patient was required to be ≥6 years and to have an IQ over 75 as assessed with either the Wechsler Intelligence Scale for Children (WISC; Tewes, Rossmann, & Schallberger, [1999](#ajmgb32695-bib-0064){ref-type="ref"}; Wechsler, [1991](#ajmgb32695-bib-0073){ref-type="ref"}), the Kaufman Assessment Battery for Children (K‐ABC; Kaufman & Kaufman, [1983](#ajmgb32695-bib-0030){ref-type="ref"}; Melchers & Preuss, [1994](#ajmgb32695-bib-0046){ref-type="ref"}), the Culture Fair Test (CFT‐20‐R; Weiss, [2006](#ajmgb32695-bib-0075){ref-type="ref"}), Snijders‐Oomen Nonverbal Intelligence Test (SON‐R; Tellegen, Winkel, & Laros, [2003](#ajmgb32695-bib-0063){ref-type="ref"}) or Intelligence and Development Scales (IDS; Grob, Meyer, & Hagmann‐von Arx, [2009](#ajmgb32695-bib-0024){ref-type="ref"}). Exclusion criteria were: (a) potentially confounding and severe psychiatric diagnoses such as psychosis, any pervasive developmental disorder, primary mood or anxiety disorder, and Tourette\'s disorder, (b) neurological disorders such as epilepsy, (c) a history of any acquired brain damage or evidence of the fetal alcohol syndrome, (d) premature deliveries (delivery before 37th gestational week), and/or (e) maternal reports of severe prenatal, perinatal or postnatal complications.

In the case--control setting, the 196 index patients (males = 148, females = 48) were compared to genetically independent 124 Caucasian healthy controls (males = 72, females = 52, aged between 5 and 18 years) who were recruited at the Departments of Child and Adolescent Psychiatry of the Universities of Würzburg and Zurich. The index patient in the case--control study was part of the family study and the inclusion and exclusion criteria were the same as described above. Informed written consent was obtained in all cases from the participants and their parents. The study was approved by the ethical commissions of all involved universities in accordance with the latest version of the Declaration of Helsinki, including an ethical permission granted by the Ethic Committees from Würzburg, and the Cantonal Ethic Committee of Zurich (Ref. Nr. KFO 140/03 and KEK‐ZH‐Nr. 2016--00101). Demographic characteristics of Zurich ADHD cases and controls are summarized in Supporting Information Table S2a and S2b.

### 2.1.2. Replication samples (Hungarian and German cADHD) {#ajmgb32695-sec-0005}

The SNP association study was replicated in samples from Budapest, Hungary and Würzburg, Germany, which were described in detail previously (Kereszturi et al., [2007](#ajmgb32695-bib-0031){ref-type="ref"}; Walitza et al., [2005](#ajmgb32695-bib-0071){ref-type="ref"}). The replication sample included child and adolescent patients with ADHD and their parents (Würzburg; Walitza et al., [2005](#ajmgb32695-bib-0071){ref-type="ref"}), and ADHD patients, their available parents and unrelated controls (Budapest; Kereszturi et al., [2007](#ajmgb32695-bib-0031){ref-type="ref"}) with the following characteristics: There were 171 Caucasian nuclear families (106 families with both parents and 65 families with one parent) with additional cADHD cases and healthy young adult controls from Budapest. In the family‐based setting this yielded 181 probands with ADHD according to ICD‐10 (males = 157, females = 24) and 312 controls (males = 132, females = 180), whereas the case--control study consisted of 206 cADHD patients (males = 180, females = 26, aged between 5 and 17 years) and 262 healthy controls (males = 160, females = 102, aged between 18 and 29 years). The Würzburg‐trios and duos included 387 children and adolescents affected with ADHD also according to ICD‐10 (males = 296, females = 91) and 540 controls (males = 275, females = 265).

The Ethics Committees of the respective universities approved the study and written informed consents were obtained from the participants and their parents after the study have been fully explained (see previous publications; Kereszturi et al., [2007](#ajmgb32695-bib-0031){ref-type="ref"}; Walitza et al., [2005](#ajmgb32695-bib-0071){ref-type="ref"}).

### 2.1.3. Genotyping {#ajmgb32695-sec-0006}

The study samples were genotyped for rs4988319 and rs3736228 in *LRP5*, and rs1012672 and rs2302685 in *LRP6*, which were chosen based on previous genetic findings (described in the introduction) and the availability of validated or functionally tested TaqMan assays. DNA was isolated either from whole blood collected in ethylenediaminetetraacetic acid tubes using QIAamp DNA Blood Maxi Kit (Qiagen), or from saliva collected in the Oragene DNA collection kit (DNA Genotek, Canada) and isolated as per manufacturer\'s protocol. DNA concentrations, A260/A280, and A260/A230 ratios were measured using a spectrophotometer (NanoVue Plus, GE). The study population was genotyped with DNA (10 ng), TaqMan® Genotyping Master Mix (Applied Biosystems), and *LRP5* or *LRP6* SNP Genotyping Assays (Applied Biosystems---see Supporting Information Table S3) combined in a 384‐well plate. Real‐time PCR was performed in a C1000™ CFX384™ Thermal cycler (Bio‐Rad) using TaqMan® SNP Genotyping Assay PCR standard protocol. Genotypes were determined by the allelic discrimination program of Bio‐Rad CFX Manager™ Software version 2.1. Samples were run in duplicates to ensure reproducibility. In case of ambiguity in duplicates, genotyping was repeated in a separate run to resolve the discrepancy. No‐template controls were included in every run to exclude impurities.

### 2.1.4. Statistical analysis {#ajmgb32695-sec-0007}

All association studies were run on the PLINK v1.7 (URL: <http://pngu.mgh.harvard.edu/purcell/plink/>; Purcell et al., [2007](#ajmgb32695-bib-0055){ref-type="ref"}). Each study group (case--control study) was tested for Hardy--Weinberg equilibrium (Supporting Information Table S4). For the case--control association study, the Fisher\'s Exact Test was conducted and significance was set at *p* \< .00417 following multiple testing corrections (four SNPs, three groups = male, female, and all together). For the family association study, Mendel errors test (none were found) followed by the transmission disequilibrium test was conducted as well as a parent‐of‐origin analysis. Power was calculated using the Genetic Association Study (GAS) calculator <http://csg.sph.umich.edu/abecasis/cats/gas_power_calculator/index.html>.

### 2.1.5. Meta‐analysis {#ajmgb32695-sec-0008}

We conducted literature search to find any publications that described genetic association studies for *LRP5* and *LRP6* SNPs in connection to ADHD or GWAS in European (Caucasian) ADHD. No previous GAS was available for these two genes in ADHD. However, we could find the GWAS by Hinney et al. ([2011](#ajmgb32695-bib-0028){ref-type="ref"}), and the GWAS results of the PGC (Demontis et al., [2017](#ajmgb32695-bib-0019){ref-type="ref"}; Martin et al., [2018](#ajmgb32695-bib-0045){ref-type="ref"}) containing the SNPs analyzed in the current study. A meta‐analysis was conducted with the currently studied populations (Zurich, Budapest, and Würzburg) together with the cADHD results from Hinney et al. ([2011](#ajmgb32695-bib-0028){ref-type="ref"}) using the MIX 2.0 Pro v.2.0.1.4 (BiostatXL, 2011. <http://www.meta-analysis-made-easy.com>). The PGC‐ADHD results were not added into the meta‐analysis, as the results from the PGC GWAS would outweigh our three study samples, due to a larger sample size, as well as high heterogeneity since the PGC did not contain solely cADHD patients. Therefore, the results of the PGC‐ADHD were used only as comparison to the meta‐analysis results. Variability, due to between‐study heterogeneity, was estimated by *I* ^2^ and funnel plots (Supporting Information Table S5), followed by Begg\'s and Egger\'s regression test (Begg & Mazumdar, [1994](#ajmgb32695-bib-0005){ref-type="ref"}; Egger, Davey Smith, Schneider, & Minder, [1997](#ajmgb32695-bib-0021){ref-type="ref"}; Supporting Information Table S6) to evaluate publication bias due to heterogeneity, and the quality of the studies was assessed based on traditional epidemiological considerations as previously described in Liu et al. ([2015](#ajmgb32695-bib-0040){ref-type="ref"}) (Supporting Information Table S7 and S8). Following heterogeneity tests, fixed‐effects model was used to conduct the mea‐analysis when *I* ^2^ demonstrated no significant heterogeneity in the samples, whereas the random‐effects model meta‐analysis was run if heterogeneity was found (see type of test used for each test in Supporting Information Table S5).

### 2.1.6. Gene expression patterns and functional findings {#ajmgb32695-sec-0009}

To elaborate whether the four SNPs studied may have any potential functional effects on gene expression or epigenetic targets, the SNPnexus (<http://www.snp-nexus.org/>; Chelala, Khan, & Lemoine, [2009](#ajmgb32695-bib-0012){ref-type="ref"}; Dayem Ullah, Lemoine, & Chelala, [2012](#ajmgb32695-bib-0016){ref-type="ref"}; Dayem Ullah, Lemoine, & Chelala, [2013](#ajmgb32695-bib-0017){ref-type="ref"}) and eQTLs for both genes according to GTEx (<https://www.gtexportal.org/home/>; Consortium, [2013](#ajmgb32695-bib-0013){ref-type="ref"}) were run (see results Supporting Information Table S1). Furthermore, the gene‐expression profiles in various brain regions compared to whole blood and nerve‐tibial were extracted from GTEx data for *LRP5* and *LRP6* stratified by sex. Welch two‐sided *t* test was conducted between the two sexes for each of the tissue analyzed. Since ADHD is a neurodevelopmental disorder, and most likely the transcript patterns alter with age, we downloaded the expression profiles of the two genes from the BRAINSPAN consortium (<http://www.brainspan.org/>) focusing on several brain regions (dorsolateral prefrontal cortex, orbital frontal cortex, hippocampus, amygdala, striatum, and cerebellum) to create age trajectories for the expression of the two genes.

3. RESULTS {#ajmgb32695-sec-0010}
==========

3.1. LRP5 and LRP6 genetic associations in cADHD {#ajmgb32695-sec-0011}
------------------------------------------------

Linkage disequilibrium (LD) values between the two *LRP5* SNPs and the *LRP6* SNPs demonstrated weak linkage in all studied cohorts, similar to the NIH LDlink data for European populations (extracted from <https://analysistools.nci.nih.gov/LDlink/?tab=home>; see Supporting Information Table S9). Therefore, we could conclude that the resulted association was independent of each other.

In the case--control study a nominal significant association between *LRP5* rs3736228 and ADHD was observed in the Zurich sample (OR = 2.043, 95% CI 1.209--3.453, *p* = .0067, power = 0.944; Supporting Information Table S10). This association was significant after stratification by sex only in ADHD females (OR = 3.614, 95% CI 1.519--8.6, *p* = .0024, power = 1.0). Nominal significant sex‐specific association was also present at this *LRP5* SNP in the Budapest case--control sample (OR = 2.549, 95% CI 1.218--5.334, *p* = .0109, power = 0.995). Moreover, *LRP5* rs4988319 was nominally associated with ADHD in the female subgroup from Budapest (OR = 2.12, 95% CI 1.007--4.462, *p* = .0444, power = 0.923).

Although no significant association between *LRP6* rs1012672 or rs2302685 and ADHD was detected in any one of the three European samples, some tendencies could be observed (Supporting Information Table S10). However, following sex stratification, nominal significant association of the *LRP6* rs2302685 was observed among males using the case--control design at both the Zurich and Budapest ADHD samples (OR = 1.971, 95% CI 1.13--3.438, *p* = .0159, power = 0.904; OR = 1.516, 95% CI 1.009--2.277, *p* = .0441, power = 0.519, respectively). Family based association analyses of the *LRP6* SNPs yielded only tendency toward association in the Zurich sample (Supporting Information Table S10).

3.2. Meta‐analysis of LRP5 and LRP6 SNPs in children and adolescents with ADHD {#ajmgb32695-sec-0012}
------------------------------------------------------------------------------

In order to evaluate the associations found with ADHD, we performed a meta‐analysis including both the case--control and family studies (Zurich, Würzburg, and Budapest) with available published data from Hinney et al. ([2011](#ajmgb32695-bib-0028){ref-type="ref"}). As described in the methods section, the large PGC‐ADHD GWAS (Demontis et al., [2017](#ajmgb32695-bib-0019){ref-type="ref"}; Martin et al., [2018](#ajmgb32695-bib-0045){ref-type="ref"}) was not added into the current meta‐analysis and was only used as a comparison study, because it consisted of both cADHD and aADHD, as well as due to its weight comparing to the other studies (Supporting Information Table S7‐S8). Following heterogeneity analysis (Supporting Information Table S5 and Figure S1) a fixed‐effect model analysis was conducted since no significant heterogeneity was detected. At the *LRP5* SNPs we could not find significant association with cADHD (Figures [1](#ajmgb32695-fig-0001){ref-type="fig"}a and [2](#ajmgb32695-fig-0002){ref-type="fig"}a). On the other hand, a tendency was observed at *LRP6* rs1012672 (total *n* = 4,712; OR = 1.262, *p* = .0559, power = 0.884; Figure [3](#ajmgb32695-fig-0003){ref-type="fig"}a), and a nominal significant association was detected at *LRP6* rs2302685 with ADHD (total *n* = 2,917; OR = 1.206, 95% CI 1.03--1.413; *p* = .0197; power = 0.794; Figure [4](#ajmgb32695-fig-0004){ref-type="fig"}a).

![Summary and meta‐analysis of all cohorts and published association analyses of the *LRP5* (rs4988319) gene variation with attention‐deficit hyperactivity disorder (ADHD) following sex stratification. (a) Forest plot for rs4988319 in male/female combined cohorts. (b) Forest plot for rs4988319 in males. (c) Forest plot for rs4988319 in females. Black whiskers in the forest plot represent 95% confidence intervals (CI) for odds ratio; the weight of the study is reflected in symbol size. Sample demographics, individual statistics, heterogeneity, literature bias statistics, quality assessments and scores, and type of tests was summarized in Supporting Information Tables S5--S9. Abbreviations: CC = case--control; TDT = transmission disequilibrium test \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJMG-180-365-g001){#ajmgb32695-fig-0001}

![Summary and meta‐analysis of all cohorts and published association analyses of the *LRP5* (rs3736228) gene variation with attention‐deficit hyperactivity disorder (ADHD) following sex stratification. (a) Forest plot for rs3736228 in male/female combined cohorts. (b) Forest plot for rs3736228 in males. (c) Forest plot for rs3736228 in females. Black whiskers in the forest plot represent 95% confidence intervals (CI) for odds ratio; the weight of the study is reflected in symbol size. Sample demographics, individual statistics, heterogeneity, literature bias statistics, quality assessments and scores, and type of tests was summarized in Supporting Information Tables S5--S9. Abbreviations: CC = case--control; TDT = transmission disequilibrium test \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJMG-180-365-g002){#ajmgb32695-fig-0002}

![Summary and meta‐analysis of all cohorts and published association analyses of the *LRP6* (rs1012672) gene variation with attention‐deficit hyperactivity disorder (ADHD) following sex stratification. (a) Forest plot for rs1012672 in male/female combined cohorts. (b) Forest plot for rs1012672 in males. (c) Forest plot for rs1012672 in females. Black whiskers in the forest plot represent 95% confidence intervals (CI) for odds ratio; the weight of the study is reflected in symbol size. Sample demographics, individual statistics, heterogeneity, literature bias statistics, quality assessments and scores, and type of tests was summarized in Supporting Information Tables S5--S9. Abbreviations: CC = case--control; TDT = transmission disequilibrium test \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJMG-180-365-g003){#ajmgb32695-fig-0003}

![Summary and meta‐analysis of all cohorts and published association analyses of the *LRP6* (rs2302685) gene variation with attention‐deficit hyperactivity disorder (ADHD) following sex stratification. (a) Forest plot for rs2302685 in male/female combined cohorts. (b) Forest plot for rs2302685 in males. (c) Forest plot for rs2302685 in females. Black whiskers in the forest plot represent 95% confidence intervals (CI) for odds ratio; the weight of the study is reflected in symbol size. Sample demographics, individual statistics, heterogeneity, literature bias statistics, quality assessments and scores, and type of tests was summarized in Supporting Information Tables S5--S9. Abbreviations: CC = case--control; TDT = transmission disequilibrium test \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](AJMG-180-365-g004){#ajmgb32695-fig-0004}

Following sex stratification, a nominal significant association of *LRP5* rs4988319 and a significant association of *LRP5* rs3736228 was observed with cADHD among females (total *n* = 229; OR = 1.8, 95% CI 1.073--3.024, *p* = .0259, power = 0.731; total *n* = 957; OR = 2.083, 95% CI 1.292--3.359, *p* = .0026, power = 0.998; respectively; Figures [1](#ajmgb32695-fig-0001){ref-type="fig"}c and [2](#ajmgb32695-fig-0002){ref-type="fig"}c). On the other hand, at *LRP6* rs2303685 significant association with cADHD was present in males (total *n* = 559; OR = 1.661, 95% CI 1.196--2.307, *p* = .0024, power = 0.846; Figure [4](#ajmgb32695-fig-0004){ref-type="fig"}b).

To test the sex effect, we ran a regression analysis (generalized linear mixed model) looking at the sex and SNP dosage and their interaction including the sites as a random effect in order to account for possible site‐effects. The regression analysis showed significant association between sex and ADHD but no significant SNP × sex interaction was detected (Supporting Information Table S11). Nevertheless, some suggestive sex effects were found supporting the meta‐analysis results, as the probability to have ADHD increased with the number of risk allele at *LRP5* rs4988319 in females (Supporting Information Figure S2a). Similarly, a modest increase for having ADHD could be seen for those with the risk allele of *LRP5* rs3736228 (Supporting Information Figure S2b). Whereas at *LRP6* rs2302685 the probability to have ADHD increased with the number of risk allele only in males (Supporting Information Figure S2d).

3.3. PGC‐ADHD GWAS results for LRP5 and LRP6 SNPs {#ajmgb32695-sec-0013}
-------------------------------------------------

In order to compare the current findings that focused on Caucasian cADHD patients, we extracted the summary statistics of the newest (November 2017) available PGC data for European ancestry ADHD patients (child and adolescent as well as adults) and then stratified data by sex (Demontis et al., [2017](#ajmgb32695-bib-0019){ref-type="ref"}; Martin et al., [2018](#ajmgb32695-bib-0045){ref-type="ref"}). Only a suggestive association was observed between ADHD and *LRP5* rs3736228 among females (OR = 1.0942, 95% CI 1.0197--1.1742, *p* = .2779). While, *LRP6* rs2302685 showed association with ADHD only in the female subgroup of the PGC cohort (OR = 1.177, 95% CI 1.0858--1.2503, *p* = .0208). Therefore, none of the associations found in the meta‐analysis could be confirmed in the PGC‐ADHD data (Supporting Information Table S10). Nevertheless, observing all SNPs\' association results of the PGC‐ADHD dataset at the *LRP5* gene (Supporting Information Figure S3), a nominally significant signal could be seen in the male/female combined population at rs4988321 (*p* = .032), which is in moderate LD with rs3736228 (*D*′ = 1.0, *R* ^2^ = 0.227 at CEU; *D*′ = 0.967, *R* ^2^ = 0.266 at EUR) but not with rs4988319 (*D*′ = 0.219, *R* ^2^ = 0.009 at CEU; *D*′ = 0.514, *R* ^2^ = 0.056 at EUR). This association was specifically stronger (*p* = .0086) at the female population in the sex stratified Manhattan plot (Supporting Information Figure S3c). Similarly, around the studied *LRP6* SNPs, some nominally significant signals could be observed in the male/female combined study population (Supporting Information Figure S4a), that were particularly enhanced in the stratified female ADHD population (Supporting Information Figure S4b).

3.4. Sex and age dependent LRP5 and LRP6 gene expression patterns in brain tissue {#ajmgb32695-sec-0014}
---------------------------------------------------------------------------------

According to GTEx database, *LRP5* transcript expression in various brain regions is rather low compared to the nerve‐tibial, but higher than whole blood samples (Supporting Information Figure S5). Similar pattern was observed for *LRP6* transcript with slightly higher expression levels in brain regions (Supporting Information Figure S6). *LRP5* transcript was expressed significantly higher in male brain‐spinal cord, whereas slightly higher expression in female could be observed in the cerebellum, nucleus accumbens, putamen, and substantia nigra, however in the last three not reaching significance. *LRP6* transcript was expressed significantly higher in male brain‐cortex, and slightly more expressed in male caudate, spinal cord, and nerve‐tibial, however not reaching significance. As the GTEx data represents aged population, age dependent gene‐expression was extracted from the BRAINSPAN database (Supporting Information Figure S7). From the six brain regions extracted, *LRP5* and *LRP6* expression show a strong age dependency with higher levels at embryonal and early postnatal stages compared to middle age subjects (up to 40 years of age), in which the expression becomes lower starting from around 19 years of age (corresponding to 1,000 weeks).

4. DISCUSSION {#ajmgb32695-sec-0015}
=============

The involvement of Wnt‐signaling in neurodevelopmental and neurodegenerative disorders have been widely discussed, particularly in ASD and AD with several studies pointing to its role in cognition and behavior (Kwan et al., [2016](#ajmgb32695-bib-0034){ref-type="ref"}; Libro, Bramanti, & Mazzon, [2016](#ajmgb32695-bib-0038){ref-type="ref"}; Mulligan & Cheyette, [2017](#ajmgb32695-bib-0047){ref-type="ref"}; Rios, Cisternas, Arrese, Barja, & Inestrosa, [2014](#ajmgb32695-bib-0056){ref-type="ref"}; Wang et al., [2017](#ajmgb32695-bib-0072){ref-type="ref"}; Zhang et al., [2014](#ajmgb32695-bib-0081){ref-type="ref"}). In the current study, we tested the hypothesis that *LRP5* and *LRP6* gene variants, coding for essential receptors for the Wnt‐pathway activation, associate with ADHD among children and adolescents, in a sex‐specific manner. Among the four studied gene variants, our meta‐analysis showed significant association between *LRP5* rs3736228 (Ala1330Val) and cADHD in girls, while *LRP6* rs2303685 (Val1062Ile) was associated with cADHD in boys. This phenomenon could also be observed in the more heterogeneous ADHD population studied in the PGC‐ADHD, consisting of both cADHD and aADHD samples, in which nominally significant SNP signals on the Manhattan plots were found to be specific for females at *LRP5*, however no clear‐cut result for *LRP6* gene variants emerged. This discrepancy between our results and the PGC‐ADHD might be due to higher heterogeneity observed in the PGC‐ADHD sample, considering the age of onset that may play a major role with these gene variants. Indeed, BRAINSPAN dataset analysis (Supporting Information Figure S7) demonstrated age‐dependent gene expression of both *LRP5* and *LRP6* with higher transcript levels at brain developmental stages while lower in adulthood. Independent to age effects, in GTEx dataset some hint for higher expression of *LRP5* in aged females and of *LRP6* in aged males was observed (Supporting Information Figures S5 and S6, respectively), point to sex‐dependent regulation.

The Wnt‐signaling genes were shown to display sex differences in gene expression levels in a study of human placental transcriptomics of male and female embryos (Sedlmeier et al., [2014](#ajmgb32695-bib-0059){ref-type="ref"}). In this study, the authors tested the effect of maternal dietary n‐3 polyunsaturated fatty acid supplementation during pregnancy, measuring the offspring\'s fat mass and development. Interestingly, the authors revealed significant sex‐dependent gene expression difference in control placentae per se, in which Wnt‐signaling genes were down regulated in male compared to female placentae (Sedlmeier et al., [2014](#ajmgb32695-bib-0059){ref-type="ref"}). Furthermore, n‐3 unsaturated fatty acid supplementation affected the placental transcriptomics much stronger in females, as demonstrated with decreased *LRP6* mRNA levels in the n‐3 supplemented female placentae (Sedlmeier et al., [2014](#ajmgb32695-bib-0059){ref-type="ref"}), whereas male placenta transcriptomics did not result in such alterations. In addition, the authors showed significant positive correlation with placental estradiol‐17β/testosterone ratio and *LRP6* expression (Sedlmeier et al., [2014](#ajmgb32695-bib-0059){ref-type="ref"}). One possible explanation to this sex‐dimorphic effect is that there is at least one estrogen receptor alpha response element within the gene body of the Wnt‐signaling genes, which might affect their transcription regulation via sex hormones (Sedlmeier et al., [2014](#ajmgb32695-bib-0059){ref-type="ref"}).

Lastly, some limitations should be mentioned, such as the relatively modest sample size of the sex‐stratified ADHD cohorts at certain gene variants in the meta‐analysis, the heterogeneity of the PGC‐ADHD used as a comparison study, and the limited number of variants studied within the two genes. Therefore, some caution should be taken at the interpretation of our results, especially at those analyses where only two independent study cohorts could be used. Nevertheless, our study\'s strength lies in the more homogenous, childhood‐onset ADHD samples recruited from European populations with the same diagnostic tools and similar inclusion/exclusion criteria.

In summary, we were able to demonstrate genetic associations between nonsynonymous *LRP5* and *LRP6* variants with cADHD in a sex‐specific manner. These results could highlight genetic variants with modified receptor functions in the Wnt‐signaling playing important role in brain development and maturation, which is particularly vulnerable in children and adolescents with ADHD. However, this hypothesis should be further investigated at the molecular and cellular levels, for example, using animal models or using induced pluripotent stem cell neuronal modeling techniques. In the light of our previous findings that methylphenidate activates Wnt‐signaling (Grünblatt et al., [2018](#ajmgb32695-bib-0025){ref-type="ref"}), we suggest that LRP5/6 coreceptors could be regarded as possible new therapeutic targets in ADHD treatment, especially in childhood when brain maturation is still ongoing.
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